Antithrombotic agents in cerebral ischaemia

Journal of Association of Physicians of India

Volumn 54, Issue JULY, 2006, Pages 555-561

  Dalal, P M ^a   Mishra, N K ^a   Bhattacharjee, Madhumita ^a   Bhat, Priya ^a  

^a LILAVATI HOSPITAL AND RESEARCH CENTRE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLASSIFICATION; HUMAN; PATHOPHYSIOLOGY; REVIEW; RISK ASSESSMENT; RISK FACTOR; STROKE;

ANTICOAGULANTS; ASPIRIN; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FIBRINOLYTIC AGENTS; HUMANS; RISK ASSESSMENT; RISK FACTORS; STROKE;

EID: 33745870482     PISSN: 00045772     EISSN: 00045772     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Goldstein M, Barnett HJM, Orgogozo JM, Sartorius N, et al. Sttoke 1989. Recommendations on stroke prevention, diagnosis and therapy. Report of the WHO Task force on Stroke and other Cerebrovascular Disorders. Stroke 1989;20:1407-31.
2. Dalal PM. Burden of stroke - Indian perspective. J Assoc Physicians India 2004;52:695-6.
3. Dalal PM. Strokes (CVD) in India: Issues in primary and secondary prevention. Neurology India 2002;50:S2-S7
4. Dalal PM. Ischaemic Strokes: Management in first six hours. Neurology India 2001;49:104-115.
5. Socco RL, Foulkes MA, Mohr JP, et al. Determinants of early recurrence of cerebral infarction. The Stroke Data Bank. Stroke 1989;20:983-9.
6. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endartectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991;325:445-53.
7. Rundek T, Elkind M, Chen X. Increased early stroke recurrence among patients with extracranial and intracranial atherosclerosis. Neurology 1998;50:A75.
8. Carter AB. Anticoagulant treatment in progressing stroke. BMJ 1961;2:70-73.
9. Baker RN, Broward JA, Fang HC. Anticoagulant therapy in cerebral infarction. Neurology 1962;12:823-35.
10. Fisher CM. Use of anticoagulants in cerebral thrombosis. Neurology 1958;8:311-32.
11. Fisher CM. Anticoagulant therapy in cerebral thrombosis and cerebral embolism: a national co-operative study interim report. Neurology 1961;11:32-8.
12. Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: a randomised trial. Stroke 1983;14:668-76.
13. Gregory W Albers, Pierre Amarenco, J Donald Easton, et al. Antithrombotic and thrombolytic therapy for ischaemic stroke. Chest 2004;126.3(Suppl. 483S);483-512.
14. Antithrombotic trialist's collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
15. International Stroke Trial Collaborative Group. The International stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349:1569-81.
16. Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry 1996;60:197-9.
17. The SALT Collaborative Group. Swedish Aspirin Low Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;338:1345-49.
18. Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischaemic stroke. Stroke 2000;31:1240.
19. CAPRIE Steering Committee. A randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events. (CAPRIE) Lancet 1996;348:1329-39.
20. Diener H, et al. European Stroke Prevention Study II (ESPS II). J Neurol Sci 1996;143:1-13.
21. Hankey GJ, Sudlow CLM, Dunbabin DW. Thenopyridines or Aspirin to prevent Stroke and other serious vascular events in patients at high risks of vascular disease. A systematic review of the evidence from randomized trials. Stroke 2000;31:601.
22. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and Clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high risk patients (MATCH): Randomised, double blind, placebo controlled trail. Lancet 2004;364:331-7.
23. th international stroke conference; February 2003. Abstract.
24. th Edition: Reprint 2004:557-74.
25. Atrial Fibrillation investigators. Risk factors for Stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
26. Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in-patients with non-valvular atrial fibrillation: A multicentre, prospective, randomized trial. Stroke 2000;31:817.
27. Kay R, Wong KS, Yu YL et al. Low-molecular-weight heparin for the treatment of acute ischaemic stroke. New England Journal of Medicine 1995;333:1588-93.
28. Harold P Adams. Emergent use of anticoagulation for treatment of patients with ischaemic stroke. Stroke 2002;33:856-61.
29. Publication Committee for the Trial of Org 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischaemic stroke. JAMA 1998;279:1265-72.
30. Berge E, Abdelnoor M, Nakstad PH, et al. Low molecular weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation : a double blind randomised study. HAEST Study Group. Heparin in acute embolic stroke trial. Lancet 2000;355:1205-10.
31. Hans Christoph Diener et al. Treatment of acute ischaemic stroke with the LMW heparin certoparin: results of the TOPAS trial. Therapy of Patients with Acute Stroke [TOPAS] investigators. Randomized, double-blind, dose-finding multicenter trial in patients with acute ischemic stroke. Stroke 2001;32:22-9.
32. Bath PM, Lindenstrom E, Boysen G, et al. Conducted a randomised aspirin-controlled trial studying the Tinzaparin in acute ischaemic stroke (TAIST).
33. Gubitz G, Sandercock P, Counsell C. Anticoagulants for acute ischaemic stroke (Cochrane Review) The Cochrane Library, Issue 2, 2005. Chichester, UK: John Wiley and Sons, Ltd.
34. The Cochrane Database of Systematic Reviews 2004, Issue 2. Art. No.: CD000024.pub2. DOI: 10.1002/14651858.CD000024.pub2.
35. EAFT Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.
36. Ji Y Chong, Jay P Mohr. Anticoagulation and platelet antiaggregation therapy in stroke prevention. Current Opinion in Neurology 2005,18:53-57.
37. Hart RG, Halperin JL, Pearce LA, et al. Lessons from the stroke prevention in atrial fibrillation trials. Ann Intern Med 2003;138:831-8.
38. Mohr JP, Thompson JLP, Lazar RM, et al. A comparison of Warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444-51.
39. Chimowitz MI, Lynn M, Howlett-Smith H, et al. Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Trial: final results. Presented at the American Heart Association International Stroke Conference, 2004 (Abstract). Stroke 2004;35:235.
40. Algra A, De Schryver ELLM, van Gijn, et al. Oral anticoagulants versus antiplatelet theory for preventing further vascular events after transient ischemic attack or minor stroke of presumed arterial origin. The Cochrane library 2004.
41. Kennedy J, Buchan AM. Ever decreasing circles: advances in antiplatelet therapy and anticoagulation. Stroke 2003;34:348-50.
42. Frey JL. The result of MATCH : Light or heat? Lancet Neurology 2004;3:645.